AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Heterogeneity of Treatment Effects in Sepsis Trials
I think there is high internal validity, negligible crossover, few protocol violations, excellent follow-up. But this really 7% of grown negative sepsis sounds too much. We are not seeing 70% of identifying cases of sepsis. So I'm not sure how much this is generalizable. And the delivery, it's so well described. All the details, duration of therapy, adherence, similar doses, few calls over. It's really well-designed and well-written manuscript.